ERBB2 and gastric cancer: Recently, a multi-center phase II trial evaluated the safety and efficacy of quadruplet regimen (pembrolizumab, trastuzumab, and doublet chemotherapy) as first-line therapy for unresectable or metastatic HER2-positive advanced GC.